American Society of Hirudotherapy

Anterior approach to posterior auricular artery in microvascular anastomosis - a new concept in replanting amputated ears - experience from four successful cases and literature review

Hong Ha N, Thanh Huyen TT (2025) · Acta Chirurgiae Plasticae · n=4

Observational study: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Design
single-institution case series of 4 successful microsurgical auricular replantations using novel anterior approach (February 2012-July 2022)
Sample size (n)
4
Intervention
Microsurgical ear replantation via supine position and anterior observation of posterior auricular artery (0.4-0.5 mm diameter); leech therapy 10-14 days postoperatively in 2 cases where venous anastomosis could not be achieved
Main result
All 4 cases (100%) successful with anterior approach; 2/4 patients required 10-14 days of leech therapy for venous drainage when vein anastomosis impossible; ischemia duration 4-14 hours; blood transfusion 3-4 units
Follow-up duration
Postoperative + long-term aesthetic assessment

Key Findings

  • Novel anterior approach for posterior auricular artery exposure
  • 100% success rate in 4 cases (2012-2022)
  • Extended leech protocol 10-14 days for artery-only cases
  • Traffic accidents (3/4) and violence (1/4) as causes
  • Posterior auricular artery diameter 0.4-0.5 mm achievable

Limitations

  • Small case series (n=4) over 10 years
  • Single institution experience
  • Novel approach without comparative cohort
  • Limited long-term aesthetic outcome data
  • Acta Chirurgiae Plasticae has limited international visibility

Clinical Implications

Hong Ha 2025 contributes a novel anterior surgical approach plus protocol for extended (10-14 day) leech therapy in artery-only auricular replantation. For US clinicians under K040187, this provides duration evidence beyond typical 5-7 day protocols and validates leech adjunct in artery-only scenarios when venous anastomosis is technically impossible.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.